BridgeBio Oncology Therapeutics Inc (BBOT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-26

$2.64-0.75%

Close 2026-10-26 · 1-day change

Investment OutlookAs of Oct 26, 2026

What could strengthen or challenge BridgeBio Oncology Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.668
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.586
Annual ending 2027-12-31
Revenue	—	29.05M
EPS	—	-2.518

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Develop BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers	A supporting condition in BridgeBio Oncology Therapeutics Inc's published investment case. The stated target is data updates for BBO-11818 expected in Q4 2026.	Intact	data updates for BBO-11818 are delayed beyond Q4 2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 26, 2026Last status assessment Oct 26, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q3. BBOT is advancing BBO-11818 and BBO-10203 combination studies in KRAS-mutant colorectal and pancreatic cancers, with monotherapy data updates expected in Q4 2026 and combination data in mid-2027. This strategic focus is supported by ongoing clinical enrollment and planned data milestones, indicating active development progress. Delivery assessment Oct 26, 2026
Advance BBO-8520 in combination with pembrolizumab for 2L+ NSCLC	A primary condition in BridgeBio Oncology Therapeutics Inc's published investment case. The stated target is >=75% overall response rate.	Intact	overall response rate falls below 75%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 26, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q3. BBOT prioritized advancing BBO-8520 combined with pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC patients, supported by a 75% ORR at 500 mg QD dose and 63% ORR monotherapy in naïve patients. The company reported $344.1 million cash as of 2026-Q2, providing runway into 2028. This is a new strategic focus with promising clinical data and solid financial backing. Delivery assessment Oct 26, 2026
Maintain strong financial position with cash runway into 2028	A supporting condition in BridgeBio Oncology Therapeutics Inc's published investment case. The stated target is cash runway into 2028.	Intact	cash position falls below $344 million	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 26, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q3. BBOT reported $344.1 million in cash and equivalents as of 2026-Q2, which management states will fund operations into 2028. This financial position supports ongoing clinical development priorities. No prior quarters in the supplied data restated this cash runway, so trajectory assessment is based on current disclosure. Delivery assessment Oct 26, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.52

$-2.48 → $-2.52 · observed estimates

FY2027 revenue$0.03B

$0.03B → $0.03B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-09-07	$-2.48	$29,051,857	7 / 9
2026-09-08	$-2.48	$29,051,857	7 / 9
2026-09-09	$-2.48	$29,051,857	7 / 9
2026-09-10	$-2.48	$29,051,857	7 / 9
2026-09-11	$-2.49	$29,051,857	7 / 9
2026-09-12	$-2.49	$29,051,857	7 / 9
2026-09-13	$-2.49	$29,051,857	7 / 9
2026-09-14	$-2.49	$29,051,857	7 / 9
2026-09-15	$-2.49	$29,051,857	7 / 9
2026-09-16	$-2.49	$29,051,857	7 / 9
2026-09-17	$-2.49	$29,051,857	7 / 9
2026-09-18	$-2.49	$29,051,857	7 / 9
2026-09-19	$-2.49	$29,051,857	7 / 9
2026-09-20	$-2.49	$29,051,857	7 / 9
2026-09-21	$-2.49	$29,051,857	7 / 9
2026-09-22	$-2.49	$29,051,857	7 / 9
2026-09-23	$-2.49	$29,051,857	7 / 9
2026-09-24	$-2.49	$29,051,857	7 / 9
2026-09-25	$-2.49	$29,051,857	7 / 9
2026-09-26	$-2.49	$29,051,857	7 / 9
2026-09-27	$-2.49	$29,051,857	7 / 9
2026-09-28	$-2.49	$29,051,857	7 / 9
2026-09-29	$-2.49	$29,051,857	7 / 9
2026-09-30	$-2.49	$29,051,857	7 / 9
2026-10-01	$-2.49	$29,051,857	7 / 9
2026-10-02	$-2.49	$29,051,857	7 / 9
2026-10-03	$-2.49	$29,051,857	7 / 9
2026-10-04	$-2.49	$29,051,857	7 / 9
2026-10-05	$-2.49	$29,051,857	7 / 9
2026-10-06	$-2.49	$29,051,857	7 / 9
2026-10-07	$-2.49	$29,051,857	7 / 9
2026-10-08	$-2.49	$29,051,857	7 / 9
2026-10-09	$-2.49	$29,051,857	7 / 9
2026-10-10	$-2.49	$29,051,857	7 / 9
2026-10-11	$-2.49	$29,051,857	7 / 9
2026-10-12	$-2.49	$29,051,857	7 / 9
2026-10-13	$-2.49	$29,051,857	7 / 9
2026-10-14	$-2.49	$29,051,857	7 / 9
2026-10-15	$-2.49	$29,051,857	7 / 9
2026-10-16	$-2.49	$29,051,857	7 / 9
2026-10-17	$-2.49	$29,051,857	7 / 9
2026-10-18	$-2.49	$29,051,857	7 / 9
2026-10-19	$-2.49	$29,051,857	7 / 9
2026-10-20	$-2.49	$29,051,857	7 / 9
2026-10-21	$-2.51	$29,051,857	7 / 9
2026-10-22	$-2.52	$29,051,857	7 / 9
2026-10-23	$-2.52	$29,051,857	7 / 9
2026-10-24	$-2.52	$29,051,857	7 / 9
2026-10-25	$-2.52	$29,051,857	7 / 9
2026-10-26	$-2.52	$29,051,857	7 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	0	0
2026-06-01	10	0	0
2026-07-01	11	0	0
2026-08-01	11	0	0
2026-09-01	12	0	0
2026-10-01	12	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 27–Oct 26 · 2 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 27, 2026–Oct 26, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Develop BBO-11818 and BBO-10203 combinations in KRAS-mutant cancersQualitative condition
Advance BBO-8520 in combination with pembrolizumab for 2L+ NSCLCDirect metric needs a verified mapping
Maintain strong financial position with cash runway into 2028Direct metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-80.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

BridgeBio Oncology Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, clinical-stage biotechnology story, not a proven earnings compounder. The long-term thesis is on watch: management has named development priorities, but recent financial performance is weak and confidence in the overall evidence is low.

What's priced into BridgeBio Oncology Therapeutics Inc

The supplied valuation tag says expectations are justified, with no fragility gates triggered, while the expectations-gap measure is negative. Together, these signals do not establish that BBOT is cheap or expensive versus peers, and the evidence gives little detail on what specific market expectations are embedded.

What the fundamentals likely do

Near term, repeated earnings misses and a high estimated chance of another miss point to continued reporting risk. Over the multi-year view, progress depends on advancing its KRAS cancer programs; reported cash is expected to fund operations into 2028, but the snapshot does not establish how clinical outcomes will develop.

What BridgeBio Oncology Therapeutics Inc hinges on

The main swing factor is whether BBO-8520 and the BBO-11818 and BBO-10203 programs produce useful follow-up data at the stated milestones. Weakening jobs data could weigh on cyclical names, while healthcare bellwether results may support or weaken sector momentum; these broader signals do not resolve BBOT’s company-specific clinical uncertainty.